Prognostic impact of acute myeloid leukemia classification: Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival

American Journal of Clinical Pathology

Volumn 119, Issue 5, 2003, Pages 672-680

  Arber, Daniel A ^a,b   Stein, Anthony S ^a   Carter, Nora H ^a   Ikle, David ^a   Forman, Stephen J ^a   Slovak, Marilyn L ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute myeloid leukemia; Classification; FAB; French American British classification; World Health Organization

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CELL LINEAGE; CELL SURVIVAL; CHILD; CHROMOSOME 11Q; CONTROLLED STUDY; CYTOGENETICS; DYSPLASIA; FEMALE; FRENCH AMERICAN BRITISH COOPERATIVE GROUP CLASSIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYELOBLAST; MYELODYSPLASIA; PRIORITY JOURNAL; PROGNOSIS; REALISTIC PATHOLOGIC CLASSIFICATION; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TUMOR CLASSIFICATION; WORLD HEALTH ORGANIZATION; ACUTE DISEASE; BONE MARROW CELL; CHROMOSOME ABERRATION; CLASSIFICATION; GENETICS; INFANT; MIDDLE AGED; MYELOID LEUKEMIA; PATHOLOGY; PRESCHOOL CHILD;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; BONE MARROW CELLS; CELL LINEAGE; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; INFANT; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; WORLD HEALTH ORGANIZATION;

EID: 85047688311     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/EM7KCQR4GLMHRCX4     Document Type: Article

References (36)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukemias. Br J Haematol. 1976;33:451-458.
2. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:626-629.
3. Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001. World Health Organization Classification of Tumours.
4. Arber DA. Realistic pathologic classification of acute myeloid leukemias. Am J Clin Pathol. 2001;115:552-560.
5. Martinez-Climent JA, Lane NJ, Rubin CM, et al. Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. Leukemia. 1995;9:95-101.
6. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.
7. Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group study: POG 8821. Blood. 1999;94:3707-3716.
8. Fenaux P, Preudhomme C, Lai JL, et al. Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: report on 283 cases. Br J Haematol. 1989;73:61-67.
9. Dastugue N, Payen C, Lafage-Pochitaloff M, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. Leukemia. 1995;9:1491-1498.
10. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075-4083.
11. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312-1320.
12. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173-4179.
13. Schoch C, Kern W, Krawitz P, et al. Dependence of age-specific incidence of acute myeloid leukemia on karyotype [letter]. Blood. 2001;98:3500.
14. Paietta E, Andersen J, Gallagher R, et al. The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study. Leukemia. 1994;8:1108-1112.
15. Guglielmi C, Martelli MP, Diverio D, et al. Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome: a cooperative Italian study on 196 cases. Br J Haematol. 1998;102:1035-1041.
16. Khalidi HS, Medeiros LJ, Chang KL, et al. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities. Am J Clin Pathol. 1998;109:211-220.
17. Kita K, Nakase K, Miwa H, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood. 1992;80:470-477.
18. Nakamura H, Kuriyama K, Sadamori N, et al. Morphological subtyping of acute myeloid leukemia with maturation (AML-M2): homogeneous pink-colored cytoplasm of mature neutrophils is most characteristic of AML-M2 with t(8;21). Leukemia. 1997;11:651-655.
19. Hurwitz CA, Raimondi SC, Head D, et al. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood. 1992;80:3182-3188.
20. Arber DA, Glackin C, Lowe G, et al. Presence of t(8;21) (q22;q22) in myeloperoxidase-positive, myeloid surface antigen-negative acute myeloid leukemia. Am J Clin Pathol. 1997;107:68-73.
21. Larson RA, Williams SF, Le Beau MM, et al. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. Blood. 1986;68:1242-1249.
22. Le Beau MM, Larson RA, Bitter MA, et al. Association of an inversion of chromosome 16 and abnormal marrow eosinophils in acute myelomonocytic leukemia. N Engl J Med. 1983;309:630-636.
23. Adriaansen HJ, te Boekhorst PAW, Hagemeijer AM, et al. Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression. Blood. 1993;81:3043-3051.
24. Paietta E, Wiemik PH, Andersen J, et al. Acute myeloid leukemia M4 with inv(16) (p13q22) exhibits a specific immunophenotype with CD2 expression [letter]. Blood. 1993;82:2595.
25. Goasguen JE, Matsuo T, Cox C, et al. Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival. Leukemia. 1992;6:520-525.
26. Head DR. Revised classification of acute myeloid leukemia. Leukemia. 1996;10:1826-1831.
27. Lemez P, Galikova J, Haas T. Erythroblastic and/or megakaryocytic dysplasia in de novo acute myeloid leukemias M0-M5 show relation to myelodysplastic syndromes and delimit two main categories. Leuk Res. 2000;24:207-215.
28. Gahn B, Haase D, Unterhalt M, et al. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. Leukemia. 1996;10:946-951.
29. Tamura S, Takemoto Y, Wada H, et al. Significance of trilineage myelodysplasia in de novo acute myeloid leukaemia during remission rather than at diagnosis. Br J Haematol. 1998;101:743-748.
30. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
31. Pearson K. In the chi-square test of goodness of fit. Biometrika. 1922;9:22-27.
32. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021-1028.
33. Lo Coco F, Nervi C, Avvisati G, et al. Review and meeting report: acute promyelocytic leukemia: a curable disease. Leukemia. 1998;12:1866-1880.
34. Estey E, Thall P, Beran M, et al. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 1997;90:2969-2977.
35. Ghaddar HM, Plunkett W, Kantarjian HM, et al. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia. 1994;8:1269-1274.
36. Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17:3767-3775.